ArticleBrain, behavior, & immunity - health2026
Comparative profiling of neurological and biomarker status in type 1 diabetes and multiple sclerosis: A cross-sectional observational study.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) are considered chronic organ-specific autoimmune diseases. Their high prevalence, progressive nature, impact on daily life, the need for lifelong management, and increased co-occurrence have attracted research interest. However, the comparative evaluation of neurological and cognitive status in these diseases and their impact on multimodal neurodegenerative biomarkers remains underexplored. Methods: This cross-sectional observational study included 76 participants, including 18 patients with newly diagnosed T1DM, 26 patients with relapsing-remitting MS, and 20 healthy controls (HCs). Additionally, 12 patients with long-duration T1DM were included in exploratory analyses to investigate the effects of prolonged disease exposure. Comprehensive assessments included clinical and neuropsychological evaluations, cellular immune profiles testing, alongside advanced neuroimaging techniques, such as whole-brain and regional grey matter (GM) volumetry and optical coherence tomography, for retinal nerve fibre layer (RNFL) thickness. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) levels were measured. Results: Patients with newly diagnosed MS and T1DM exhibited cognitive and mood disturbances, elevated sNfL levels, and distinct immunological and biochemical profiles compared with HCs. Patients with MS showed significant thalamic volume reduction and RNFL thinning, whereas those with T1DM did not exhibit significant GM volume loss or RNFL thinning. However, patients with advanced T1DM presented with increased sNfL concentrations and a trend towards retinal thinning. Partial correlations, controlling for age, schooling, or intracranial volume, revealed that impaired cognitive processing speed was significantly associated with higher sNfL levels, increased retinal thinning, and a smaller left thalamus volume. Discussion: Our findings emphasize the shared and distinct mechanisms of neurodegeneration underlying cognitive dysfunction in patients with newly diagnosed MS and T1DM, suggesting that both diseases involve overlapping mechanisms of immune-mediated damage and neurodegenerative processes that can contribute to the future development of neurological disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.